Titlebook: Cervical Cancer; Methods and Protocol Daniel Keppler,Athena W. Lin Book 2015 Springer Science+Business Media New York 2015 Cervix.CxCA.Drug

疾馳

名字的誤用

https://doi.org/10.1007/1-4020-4133-0d as novel chemotherapeutic agents. In this chapter, we describe an enzyme activity assay to assess the selectivity of a putative small-molecule DUB inhibitor toward a subset of DUBs in cancer cell lines.

Brittle

A Real-Time PCR Approach Based on SPF10 Primers and the INNO-LiPA HPV Genotyping Extra Assay for thet way, LiPA analysis of the HPV-negative samples can be avoided, reducing workload and cost. Here, we describe in detail a SYBR Green I-based real-time PCR assay based on SPF10 primers using the LightCycler. 480 system to generate and detect HPV amplicons, which are compatible with the LiPA assay.

啜泣

ENNUI

無目標(biāo)

HPV Binding Assay to Laminin-332/Integrin α6β4 on Human Keratinocyteshanisms will aid in the design of therapeutics against HPVs and ultimately help prevent many cancers. In this chapter, we describe the HPV binding assay to Ln-332/integrin α6β4 on human keratinocytes (ECM). We also present data and suggestions for modifying the assay for testing the specificity of H

協(xié)迫

A High-Throughput Cellular Assay to Quantify the p53-Degradation Activity of E6 from Different Humaned cells by determining the amount of E6-expression vector required to reduce by half the levels of RLuc-p53 luciferase activity (50 % effective concentration [EC.]). The high-throughput and quantitative nature of this assay makes it particularly useful to compare the p53-degradation activities of E

放逐

一大群

Factual